THE TRUTH ABOUT: 9 | History Defined

BofA Downgrades CureVac On Limited 2022 Prospects

There is limited upside from CureVac BV’s (NASDAQ: CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company’s pipeline in 2022, according to BofA Securities.

Benzinga · Jan 21, 2022

Why BofA Upgrades CH Robinson Worldwide

Brokerage carriers such as CH Robinson Worldwide Inc (NASDAQ: CHRW) are poised to benefit from continued strength in contract rates in the first half of 2022 and the subsequent “roll over as fluidity improves in the supply chain,” according to BofA Securities.

Benzinga · Jan 20, 2022

Why This Analyst Is Worried About Opendoor's iBuying Model In 2022

While Opendoor Technologies Inc (NASDAQ: OPEN) had strong revenues and increasing potential to gain market share, the iBuying model is “inherently risky, low margin, and capital intensive,” according to BofA Securities.

Benzinga · Jan 19, 2022